Table 4.
Scores for belief in illness by follow-up times for participants with newly diagnosed type 2 diabetes allocated to a structured group education programme or to usual care (control)
| Outcomes | Median (interquartile range) | Model summary* | |||
|---|---|---|---|---|---|
| Control | Intervention | Coefficient (95% CI) | P value† | ||
| Illness coherence‡: | |||||
| Baseline | 15 (12-19) | 14 (12-18) | −0.80 (−1.49 to −0.11) | ||
| 4 months | 18 (14-20) | 19 (16-20) | 2.18 (1.60 to 2.76) | <0.001 | |
| 8 months | 19 (14-20) | 20 (16-20) | 1.50 (0.90 to 2.09) | <0.001 | |
| 12 months | 19 (15-20) | 20 (17-20) | 1.22 (0.61 to 1.83) | <0.001 | |
| Overall§ | 18.3 (14-20) | 19.5 (16.3-20.5) | 1.78 (1.25 to 2.31) | <0.001 | |
| Timeline¶: | |||||
| Baseline | 20 (15-24) | 20 (17-25) | 0.88 (0.29 to 1.47) | ||
| 4 months | 20 (19-25) | 22 (20-25) | 0.60 (0.08 to 1.12) | 0.023 | |
| 8 months | 20 (17-25) | 22 (20-25) | 1.09 (0.41 to 1.77) | 0.002 | |
| 12 months | 20 (19-25) | 22 (20-25) | 0.69 (0.04 to 1.37) | 0.036 | |
| Overall§ | 20.4 (18-23) | 22 (20-24.7) | 0.83 (0.38 to 1.29) | <0.001 | |
| Personal responsibility¶: | |||||
| Baseline | 24 (22-26) | 24 (22-26) | −0.06 (−0.58 to 0.47) | ||
| 4 months | 24 (22-26) | 25 (24-28) | 1.20 (0.79 to 1.62) | <0.001 | |
| 8 months | 24 (22-26) | 25 (23-29) | 0.84 (0.40 to 1.27) | <0.001 | |
| 12 months | 24 (23-26) | 24 (23-28) | 0.51 (−0.002 to 1.027) | 0.051 | |
| Overall§ | 24 (22.5-26.3) | 25 (23.3-27.3) | 0.92 (0.56 to 1.29) | <0.001 | |
| Impact**: | |||||
| Baseline | 14 (12-17) | 14 (12-17) | −0.20 (−0.79 to 0.39) | ||
| 4 months | 13 (12-16) | 13 (11-16) | −0.07 (−0.46 to 0.32) | 0.72 | |
| 8 months | 13 (12-15) | 13 (11-16) | 0.33 (−0.16 to 0.83) | 0.19 | |
| 12 months | 13 (12-15) | 14 (12-15) | 0.04 (−0.50 to 0.58) | 0.89 | |
| Overall§ | 13 (11.3-15.7) | 13.3 (11.5-15.3) | 0.05 (−0.34 to 0.43) | 0.82 | |
| Seriousness¶: | |||||
| Baseline | 16 (15-18) | 16 (15-18) | 0.22 (−0.10 to 0.54) | ||
| 4 months | 16 (14-18) | 17 (15-19) | 1.05 (0.70 to 1.39) | <0.001 | |
| 8 months | 16 (14-18) | 17 (16-19) | 1.05 (0.66 to 1.44) | <0.001 | |
| 12 months | 16 (14-18) | 17 (15-19) | 0.85 (0.43 to 1.27) | <0.001 | |
| Overall§ | 16 (14.5-18.0) | 17.2 (15.7-19.0) | 0.97 (0.67 to 1.27) | <0.001 | |
*Coefficient represents change in mean in intervention group compared with control group. Estimates are derived using robust generalised estimating equations. Results are adjusted for baseline values and cluster effect.
†Significance of intervention term in model.
‡Score range 5-25.
§Sum of outcomes at 4, 8, and 12 months.
¶Score range 5-30.
**Score range 5-35.